162 related articles for article (PubMed ID: 1510705)
1. Primaquine metabolism by human liver microsomes: effect of other antimalarial drugs.
Bangchang KN; Karbwang J; Back DJ
Biochem Pharmacol; 1992 Aug; 44(3):587-90. PubMed ID: 1510705
[TBL] [Abstract][Full Text] [Related]
2. Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs.
Bangchang KN; Karbwang J; Back DJ
Biochem Pharmacol; 1992 May; 43(9):1957-61. PubMed ID: 1596283
[TBL] [Abstract][Full Text] [Related]
3. Effect of selected antimalarial drugs and inhibitors of cytochrome P-450 3A4 on halofantrine metabolism by human liver microsomes.
Baune B; Furlan V; Taburet AM; Farinotti R
Drug Metab Dispos; 1999 May; 27(5):565-8. PubMed ID: 10220483
[TBL] [Abstract][Full Text] [Related]
4. Metabolic interactions of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes.
Zhao XJ; Ishizaki T
Br J Clin Pharmacol; 1997 Nov; 44(5):505-11. PubMed ID: 9384469
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of primaquine by liver homogenate fractions. Evidence for monoamine oxidase and cytochrome P450 involvement in the oxidative deamination of primaquine to carboxyprimaquine.
Constantino L; Paixão P; Moreira R; Portela MJ; Do Rosario VE; Iley J
Exp Toxicol Pathol; 1999 Jul; 51(4-5):299-303. PubMed ID: 10445386
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome P(450)-dependent toxic effects of primaquine on human erythrocytes.
Ganesan S; Tekwani BL; Sahu R; Tripathi LM; Walker LA
Toxicol Appl Pharmacol; 2009 Nov; 241(1):14-22. PubMed ID: 19616568
[TBL] [Abstract][Full Text] [Related]
7. An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems.
Halliday RC; Jones BC; Smith DA; Kitteringham NR; Park BK
Br J Clin Pharmacol; 1995 Oct; 40(4):369-78. PubMed ID: 8554939
[TBL] [Abstract][Full Text] [Related]
8. Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. In vitro studies and correlation with in vivo data.
Walker DK; Alabaster CT; Congrave GS; Hargreaves MB; Hyland R; Jones BC; Reed LJ; Smith DA
Drug Metab Dispos; 1996 Apr; 24(4):447-55. PubMed ID: 8801060
[TBL] [Abstract][Full Text] [Related]
9. Dipeptide derivatives of primaquine as transmission-blocking antimalarials: effect of aliphatic side-chain acylation on the gametocytocidal activity and on the formation of carboxyprimaquine in rat liver homogenates.
Portela MJ; Moreira R; Valente E; Constantino L; Iley J; Pinto J; Rosa R; Cravo P; do Rosário VE
Pharm Res; 1999 Jun; 16(6):949-55. PubMed ID: 10397619
[TBL] [Abstract][Full Text] [Related]
10. Pathway-specific inhibition of primaquine metabolism by chloroquine/quinine.
Fasinu PS; Tekwani BL; Avula B; Chaurasiya ND; Nanayakkara NP; Wang YH; Khan IA; Walker LA
Malar J; 2016 Sep; 15(1):466. PubMed ID: 27618912
[TBL] [Abstract][Full Text] [Related]
11. Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine.
Zhang H; Coville PF; Walker RJ; Miners JO; Birkett DJ; Wanwimolruk S
Br J Clin Pharmacol; 1997 Mar; 43(3):245-52. PubMed ID: 9088578
[TBL] [Abstract][Full Text] [Related]
12. Cytochrome P450 isozymes involved in lisofylline metabolism to pentoxifylline in human liver microsomes.
Lee SH; Slattery JT
Drug Metab Dispos; 1997 Dec; 25(12):1354-8. PubMed ID: 9394024
[TBL] [Abstract][Full Text] [Related]
13. Effect of aliphatic side-chain substituents on the antimalarial activity and on the metabolism of primaquine studied using mitochondria and microsome preparations.
Baker JK; Yarber RH; Nanayakkara NP; McChesney JD; Homo F; Landau I
Pharm Res; 1990 Jan; 7(1):91-5. PubMed ID: 2300544
[TBL] [Abstract][Full Text] [Related]
14. Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions.
Prakash C; Kamel A; Cui D; Whalen RD; Miceli JJ; Tweedie D
Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):35S-42S. PubMed ID: 10771452
[TBL] [Abstract][Full Text] [Related]
15. Effect of mefloquine on hepatic drug metabolism in the rat: comparative study with primaquine.
Riviere JH; Back DJ
Biochem Pharmacol; 1985 Feb; 34(4):567-71. PubMed ID: 3871613
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of rat hepatic mixed function oxidases by antimalarial drugs: selectivity for cytochromes P-450 and P-448.
Thabrew MI; Ioannides C
Chem Biol Interact; 1984 Oct; 51(3):285-94. PubMed ID: 6488390
[TBL] [Abstract][Full Text] [Related]
17. N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine (DPPE) a chemopotentiating and cytoprotective agent in clinical trials: interaction with histamine at cytochrome P450 3A4 and other isozymes that metabolize antineoplastic drugs.
Brandes LJ; Queen GM; LaBella FS
Cancer Chemother Pharmacol; 2000; 45(4):298-304. PubMed ID: 10755318
[TBL] [Abstract][Full Text] [Related]
18. Metabolism of taxol by human and rat liver in vitro: a screen for drug interactions and interspecies differences.
Jamis-Dow CA; Klecker RW; Katki AG; Collins JM
Cancer Chemother Pharmacol; 1995; 36(2):107-14. PubMed ID: 7767945
[TBL] [Abstract][Full Text] [Related]
19. Biosynthesis of an aminopiperidino metabolite of irinotecan [7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecine] by human hepatic microsomes.
Haaz MC; Riché C; Rivory LP; Robert J
Drug Metab Dispos; 1998 Aug; 26(8):769-74. PubMed ID: 9698291
[TBL] [Abstract][Full Text] [Related]
20. In vitro characterization of 4'-(p-toluenesulfonylamide)-4-hydroxychalcone using human liver microsomes and recombinant cytochrome P450s.
Lee B; Wu Z; Lee T; Tan XF; Park KH; Liu KH
Xenobiotica; 2016; 46(4):350-6. PubMed ID: 26330107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
